Amylin Pharmaceuticals Inc. ( NASDAQ:AMLN) and Eli Lilly & Co.'s (NYSE:LLY) Byetta will have a new warning on its packaging due to the fact that the drug has been linked to dangerous inflammation of the pancreas.
The FDA stated that it has received 30 reports of patients on Byetta developed acute pancreatitis. Of the thirty patients, 27 were hospitalized and 22 improved after stopping treatment.
The injectable drug is marketed by Amylin and ELi Lilly for patients with Type 2 diabetes and over 700.000 people worldwide have used the drug since it was launched mid-year 2005.
Amylin and ELi Lilly announced that they would notify doctors of the new precaustions and will add new warnings to the label. It is already noted on the label that some patients may experience pancreatitis when taking Byetta, however, the updated label will highlight the risk and offer more guidance to doctors.
Comment Preview